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Novel cytokine and chemokine markers of hidradenitis
suppurativa reflect chronic inflammation and itch
To the Editor,
Hidradenitis suppurativa (HS) is an auto‐inflammatory skin disease
characterized by recurrent, chronic painful and pruritic inflammatory
nodules, abscesses and sinus tracts in predominantly the axillary, ingu-
inal, and gluteal areas. A key element of the HS pathophysiology is
occlusion of the follicular infundibulum and subsequent cyst forma-
tion, followed by rupture of the cyst inducing an intense inflammatory
response.1 Accordingly, identification of inflammatory markers is
important for the clinical stratification of HS and may help refining
treatment choices. To date, no studies have investigated inflammatory
protein levels in the serum/plasma and skin in parallel in a cohort of HS
patients. Therefore, the primary aim of this study was to simultane-
ously detect important cytokines and chemokines in, respectively, the
plasma and lesional skin of patients with HS at a single time point.
Blood and skin samples from 20 patients with a dermatologist‐
verified diagnosis of HS and 10 healthy controls (Data S1) were
prospectively collected in the Department of Dermatology of the
Erasmus University Medical Center and Sint Franciscus Hospital in
Rotterdam, the Netherlands. Skin samples of HS patients suffering
of Hurley I to III disease severity were taken from actively inflamed,
non‐fluctuating, indurated, erythematous lesions, or plaques recurring
on fixed locations. The research protocol was approved by the local
Institutional Review Board (reference MEC‐2013‐337/NL45264.-
078.13). All participants provided written informed consent.
Punch biopsies of 4 mm in diameter were obtained and immedi-
ately snap‐frozen in liquid nitrogen. Venous blood was collected in
vacuum EDTA tubes under sterile conditions, and after separation of
the plasma samples were aliquoted and stored at −80°C until analy-
sis. Samples were analyzed using the Meso Scale Discovery (MSD)
V‐PLEX™ Human Cytokine 30‐plex kit (K15054D; Meso Scale Dis-
covery, Gaithersburg, MD, USA) according to the manufacturers’
instructions (Data S1). Moreover, three chemokines, which have not
previously been reported to be overexpressed in HS patients, were
additionally analyzed by immunohistochemistry (Data S1).
Plasma protein concentrations were expressed as picogram (pg)
per milliliter (mL), whereas skin protein levels were normalized for
milligram (mg) tissue dry weight (pg/mg). In case, a protein level was
below the detection limit, the lowest limit of quantification (LLOQ)
was used for further calculations. If more than 50% of the samples per
analyzed protein in either the HS or the healthy control group had val-
ues below the LLOQ, values were substituted by two categories:
detectable vs non‐detectable, that is above or below the LLOQ,
respectively. For the primary objective, either the Mann‐Whitney U
test or Fisher's exact test was used to assess the null‐hypothesis that
there was no difference in the levels of individual markers between
control and HS samples. Secondly, correlations between protein levels
of plasma and lesional HS skin were calculated (Data S1). Statistical
analyses were conducted using SPSS Statistics 24.0 (IBM Corporation,
Armonk, NY, USA). A two‐sided P value below 0.05 was considered
significant. This level was corrected by a false discovery rate using the
Benjamini‐Hochberg test for multiple comparisons.
In plasma, 20 of 30 (66.7%) analytes were detected. In the skin, 25
of 26 (96.2%) proteins were detected, while four proteins (IL‐4, IL‐7,
VEGF, GM‐CSF) were not analyzed because they have not been vali-
dated for skin‐derived samples. In plasma, CCL‐26 was detected signif-
icantly more often in HS patients (16 of 20) compared with healthy
controls (2 of 10), P = 0.004 (Table 1). Accordingly, the median CCL‐
26 level in HS patients was 24.9 pg/mL, interquartile range 19.1−37.0
(Figure S1). In contrast, plasma CXCL‐10 levels were significantly
lower in HS patients, P = 0.003. In lesional skin, IL‐16 (P < 0.001), IL‐
17A (P < 0.001), CXCL‐8 (P = 0.001), plus IL‐8 HA (P = 0.011), repre-
senting very high CXCL‐8 concentrations, IL‐12/23p40 (P = 0.007),
CCL‐4 (P = 0.011), CXCL‐10 (P = 0.011) showed higher levels in HS
patients compared with healthy controls (Table 2, Figure S2). The ele-
vated CCL‐4 and CXCL‐10 protein levels in HS lesions were confirmed
by immunohistochemistry (Figure S3). A strong staining of CCL‐26
was observed in lesional skin, despite the fact that CCL‐26 protein
was not detected in lesional HS skin by the MSD assay (Table 2, Fig-
ure S3). Only weak correlations were observed between protein levels
in HS plasma and lesional skin (Data S1, Table S1).
Chemokine CCL‐26 (also known as eotaxin‐3) is a newly iden-
tified inflammatory marker in HS patients. Significant elevation of
this chemokine in the serum has previously been reported in ato-
pic dermatitis and cutaneous T‐cell lymphoma, which are charac-
terized by the infiltration of eosinophils, basophils, and specific
subpopulations of T cells,2,3 and all, like HS,4 diseases character-
ized by high pruritus scores. Interestingly, CCL‐26 was found in
Abbreviations: CCL, C-C motif ligand; CRP, C-reactive protein; CXCL, C-X-C motif ligand;
EDTA, ethylenediaminetetraacetic acid; GM-CSF, granulocyte-macrophage colony-
stimulating factor; HS, hidradenitis suppurativa; IL, interleukin; LLOQ, lowest limit of
quantification; MMP, matrix metalloproteinase; TNF, tumor necrosis factor; VEGF, vascular
endothelial growth factor.
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abundance in the HS infiltrate by immunohistochemistry, but was
not detected in skin homogenates, possibly because CCL‐26 is too
strongly bound to its receptor on the many eosinophils present in
the HS infiltrate.4
The cutaneous upregulation of IL‐16 and chemokines CCL‐4 and
CXCL‐10 is not surprising because they are produced by many
immune cells and play a crucial role in the induction and modulation
of immune responses during infection and inflammation.5,6 In addi-
tion, our results obtained in the skin confirm previous findings
demonstrating overexpression of IL‐17 pathway‐associated cytokines
and chemokines such as IL‐17A, IL‐23p40, and CXCL‐8 in HS.1 The
importance of neutrophils in the HS pathogenesis is underlined by
the increased levels of CXCL‐8 that can be cleaved by neutrophil
elastase to activate Th17 cells to produce bioactive IL‐17.7 Some pre-
viously published results, that showed significant upregulation of
TNF‐α, IL‐1ß, and IL‐10 in (peri)lesional HS skin, could not be con-
firmed statistically.8,9 This can be explained by the different
approaches as in our study biopsies were homogenized for in situ
assessment, while van der Zee et al and Kelly et al cultured the skin
biopsies for, respectively, 24 and 3 hours. This step of ex vivo cultur-
ing of skin samples allows for a prolonged production of cytokines
that may lead to higher cytokine levels in the culture media.
This study has several strengths including the in parallel
assessment of inflammatory markers in skin and plasma using a
TABLE 1 Inflammatory protein expression in the plasma of healthy control subjects and HS patients
Protein NN (n = 10) HS (n = 20) LLOQ Unadjusted
P valuepg/mL Median (IQR) or x/total Median (IQR) or x/total pg/mL
1 CXCL‐10 (IP‐10) 402.7 (328.7‐550.5) 277.4 (236.0‐328.8) 2.40 0.003*
2 CCL‐26 (Eotaxin‐3) 2/10 16/20 18 0.0041*
3 IL‐12/23p40 132.7 (97.7‐182.5) 104.0 (74.6‐127.2) 1.30 0.055
4 IL‐1α 1.8 (1.7‐3.6) 4.2 (2.4‐10.2) 0.62 0.055
5 CCL‐4 (MIP‐1β) 119.4 (66.6‐176.0) 78.5 (59.9‐102.5) 2.10 0.091
6 TNF‐β 2/10 0/20 0.28 0.103
7 IL‐1β 3/10 13/20 0.24 0.122
8 CCL‐22 (MDC) 926.2 (716.5‐1212.4) 1312.7 (1000.8‐1538.6) 38 0.155
9 INF‐γ 8.8 (5.3‐14.0) 6.9 (4.8‐8.9) 2.20 0.155
10 IL‐15 2.0 (1.7‐2.3) 1.7 (1.5‐2.1) 0.32 0.198
11 IL‐7 18.6 (14.8‐24.2) 22.3 (17.0‐30.3) 0.32 0.214
12 IL‐10 0.3 (0.2‐0.4) 0.2 (0.2‐0.3) 0.16 0.231
13 CCL‐3 (MIP‐1α) 2/10 1/20 15.60 0.251
14 CXCL‐8 (IL‐8) 8.7 (7.2‐9.7) 7.1 (6.0‐9.1) 3.80 0.286
15 IL‐16 208.0 (191.9‐287.3) 257.9 (186.1‐317.9) 4.20 0.475
16 CCL‐11 (Eotaxin‐1) 135.9 (95.6‐181.4) 151.6 (118.5‐210.1) 5.60 0.502
17 IL‐6 1.3 (0.9‐2.6) 1.1 (0.7‐2.6) 0.36 0.530
18 IL‐13 1/10 1/20 0.98 0.532
19 IL‐17A 4/10 6/20 2.10 0.690
20 CCL‐17 (TARC) 385.8 (222.6‐511.6) 325.9 (259.9‐653.7) 2.80 0.713
21 TNF‐α 2.6 (2.3‐3.2) 2.5 (2.2‐3.0) 0.64 0.779
22 CCL‐13 (MCP‐4) 188.0 (160.3‐234.8) 210.6 (120.9‐238.3) 4.80 0.880
23 CCL‐2 (MCP‐1) 85.0 (75.3‐99.1) 83.0 (62.9‐114.9) 0.22 0.983
24 VEGF 140.1 (116.0‐200.0) 155.0 (103.6‐250.7) 7 0.983
25 IL‐2 ND ND 0.68 ‐
26 IL‐4 ND ND 0.38 ‐
27 IL‐5 ND ND 0.40 ‐
28 IL‐12p70 ND ND 0.74 ‐
29 GM‐CSF ND ND 1.80 ‐
30 IL‐8 HA ND ND 344 ‐
IL‐8 HA (human antibody) has been validated for the MSD V‐PLEX™ kit and is recommended when high CXCL/IL‐8 levels are anticipated.
HS, hidradenitis suppurativa patients; IQR, interquartile range; LLOQ, lowest level of quantification; ND, not detected; NN, healthy controls; x, number
of samples with a detectable value.
*Significant after correction with the Benjamini‐Hochberg test (P < 0.0042).
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sensitive and accurate detection technique. Limitations of this
study are the limited sample size, which did not allow for a sub-
group analysis by Hurley disease severity, and the use of a pre-
defined panel of 30 cytokines and chemokines, which did not
measure all previously reported HS biomarkers including antimi-
crobial peptides.
In conclusion, CCL‐26 is a newly identified inflammatory
marker that is upregulated in the circulation of HS patients.
Besides previously demonstrated overexpression of IL‐17A, IL‐
23p40, CXCL‐8 in HS lesions, this study found IL‐16, CCL‐4,
CXCL‐10, and CCL‐26 as novel and potentially important players
in the pathogenesis of HS. The local and systemic upregulation
of CCL‐26 in HS patients can be linked to the high pruritus
score in HS. Furthermore, our results demonstrate that plasma
gives a limited reflection of the activated local cutaneous
inflammatory milieu.
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TABLE 2 Inflammatory protein expression in the skin of healthy control subjects and HS patients
Protein NN (n = 10) HS (n = 20) Unadjusted
P valuepg/mg skin tissue Median (IQR) or x/total Median (IQR) or x/total
1 IL‐16 10.90 (7.67‐13.09) 57.54 (38.50‐120.81) <0.001*
2 IL‐17A 0/10 15/20 <0.001*
3 CXCL‐8 (IL‐8) 0.30 (0.21‐1.30) 5.90 (1.25‐19.48) 0.001*
4 IL‐12/23p40 0.10 (0.08‐0.17) 0.25 (0.14‐0.47) 0.007*
5 CCL‐4 (MIP‐1β) 0.13 (0.08‐0.15) 0.62 (0.19‐1.83) 0.011*
6 CXCL‐10 (IP‐10) 0.66 (0.18‐1.10) 1.80 (1.07‐3.32) 0.011*
7 IL‐8 HA 0/10 10/20 0.011*
8 TNF‐β 1/10 9/20 0.101
9 CCL‐3 (MIP‐1α) 2/10 11/20 0.119
10 INF‐γ 3/10 13/20 0.122
11 TNF‐α 0/10 5/20 0.140
12 IL‐1β 0.13 (0.07‐0.18) 0.21 (0.08‐0.73) 0.155
13 CCL‐13 (MCP‐4) 0.66 (0.53‐0.72) 0.36 (0.25‐0.66) 0.172
14 IL‐10 0.009 (0.005‐0.011) 0.006 (0.004‐0.008) 0.183
15 CCL‐17 (TARC) 2/10 9/20 0.246
16 IL‐5 0.024 (0.019‐0.039) 0.017 (0.013‐0.029) 0.322
17 IL‐1α 1.28 (0.92‐2.10) 1.54 (0.86‐4.40) 0.350
18 IL‐2 0.035 (0.016‐0.081) 0.031 (0.023‐0.039) 0.530
19 IL‐6 0.26 (0.02‐0.41) 0.08 (0.03‐0.54) 0.530
20 CCL‐2 (MCP‐1) 3.13 (0.30‐4.82) 1.43 (0.42‐3.35) 0.588
21 IL‐15 0.029 (0.026‐0.039) 0.035 (0.026‐0.045) 0.588
22 CCL‐11 (Eotaxin‐1) 4/10 11/20 0.700
23 CCL‐22 (MDC) 1.80 (1.44‐3.44) 1.82 (1.23‐3.25) 0.983
24 IL‐13 0/10 1/20 1.000
25 IL‐12p70 3/10 6/20 1.000
26 CCL‐26 (Eotaxin‐3) ND ND ‐
27 IL‐7 NA NA ‐
28 VEGF NA NA ‐
29 IL‐4 NA NA ‐
30 GM‐CSF NA NA ‐
IL‐8 HA (human antibody) has been validated for the MSD V‐PLEX™ kit and is recommended when high CXCL/IL‐8 levels are anticipated.
HS, hidradenitis suppurativa patients; IQR, interquartile range; LLOQ, lowest level of quantification; NA, not analyzed, not validated for skin samples;
ND, not detected; NN, healthy controls; x, number of samples with a detectable value.
*Significant after correction with the Benjamini‐Hochberg test (P < 0.014).
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